---

$0.95

-0.0253 ( -2.61% ) 1.0M

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Type: All Buy Sale Start date: End date: Filter Reset

Date	Type	Amount Purchased	Purchaser
2024-02-02	Sale	-149300.00	Hadas Nicole R.
2024-02-02	Sale	-149300.00	Snow Ellen
2024-02-02	Sale	-149300.00	Dahan Michel
2024-02-02	Sale	-223950.00	Malabre Richard C
2024-02-02	Sale	-303300.00	Grund Nicholas
2024-02-02	Sale	-202200.00	Burke Steven Keith